Aurion Biotech has launched its cell therapy Vyznova for serious eye disorder bullous keratopathy in Japan, its debut market, becoming an alternative to corneal replacement using donor tissue.

Eyecare giant Alcon has bought a majority stake in cell therapy start-up Aurion Biotech, replacing the company's chief executive, in the culmination of a months-long struggle for control.

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...

Morningstar brands and products Company Portfolio ...

TOKYO, April 23, 2025--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments ...

Key leadership appointments to accelerate global clinical development of AURN001, a transformational cell therapy for corneal endothelial disease Aurion Biotech is developing AURN001, an ...